New Jersey S 1667: Prohibits excessive increases in prices charged for essential off-patent and generic prescription drugs and biological products.

Status: Introduced in the Senate, Referred to Senate Health, Human Services and Senior Citizens Committee (as of 2022-02-14)

State: New Jersey · Session: 220 · Bill: S 1667

Subjects: PHARMACEUTIC

Sponsors: Singleton, Troy

View New Jersey S 1667 on LegisTrack → — full text, sponsors, votes, campaign finance, and cross-state matches.